Volenrelaxin - Eli Lilly and Company
Alternative Names: LY-3540378Latest Information Update: 28 Apr 2024
At a glance
- Originator Eli Lilly and Company
- Class Heart failure therapies
- Mechanism of Action Relaxin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Chronic heart failure
- No development reported Heart failure
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in Singapore (IV)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in Singapore (SC)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in USA (IV)